DATE & TIME
Thursday, April 30, 2015
6:00 PM - 8:00 PM
Illumina (Multipurpose Room)
5200 Illumina Way
San Diego, CA 92122
Note: Free parking is on the Illumina campus, please follow the signage on the day of the event. Signage will direct our guests to the Illumina Multipurpose Room.
Next-Generation Sequencing (NGS) Assays and Technologies
Richard Christiansen, Associate Attorney, Kilpatrick Townsend; LES San Diego Chapter Program Chair
Brenden Gingrich, Partner, Knobbe Martens
Kevin Gunderson, Senior Director of Advanced Research, Illumina
Our experienced co-presenters will provide an exciting overview on NGS advances and its relevant applications. Additionally, our speakers will comment on the current legal state of affairs regarding NGS development. Come and learn about the new advances in this rapidly evolving discipline.
“The role of scalability in Next-Generation Sequencing (NGS) advances,” presented by Kevin Gunderson, Ph.D. (Illumina)
“The legal landscape regarding NGS and related technologies,” presented by Brenden Gingrich, Ph.D. (Knobbe Martens)
Early registration: Online, by Monday, April 27, 2015
LES Member: $40
LES Student Member: $25
Regular registration: Online & onsite, Tuesday, April 28, 2015
LES Member: $45
LES Student Member: $30
No refunds after April 27
Richard Christiansen is an Associate at Kilpatrick Stockton where he focuses his practice on all aspects of patent law. Richard’s patent expertise includes electronics, medical devices, software, clean technology, and mechanical devices. Before launching his legal career, Rich was involved in the development of diesel injection systems at Siemens VDO and was a design engineer at Raytheon Missile System where he participated in the development and testing of a new weapon system. Richard received his B.S. degree in Mechanical Engineering from Brigham Young University and his J.D. from New York University.
Dr. Gingrich’s practice focuses on the protection of intellectual property for the biotechnology and medical device industries. His expertise includes the preparation and prosecution of patent applications, counseling on patent strategy, and intellectual property due diligence for both large and small businesses, as well as individual inventors. Dr. Gingrich currently represents clients with technology in the fields of antisense therapy, molecular biology and genetics, pharmaceuticals, DNA sequencing, blood purification, microfluid processing, and surgical fasteners.
During his doctoral studies, Dr. Gingrich studied the molecular basis of complex social behavior in rodents. Prior to receiving his Ph.D., his undergraduate thesis focused on the study of artificial protein channels created using molecular biological techniques. Brenden received his Ph.D. in Neuroscience from Emory University and his J.D. from the University of Virginia School of Law. Brenden received his B.S. degree in chemistry from the University of Delaware.
Dr. Gunderson is currently Senior Director of Advanced Research at Illumina, where he spent his last 16 years overseeing R&D scientists and projects aimed at developing both DNA array and Next-Generation Sequencing (NGS) assays and technologies. These efforts helped Illumina grow from a fledgling start-up to the world’s leading provider of Genomics and NGS instruments and assays. In addition to his role at Illumina, Kevin serves on the Evonexus Committee, where he helps evaluate and mentor young technology companies. Prior to Illumina, Kevin was a research scientist at Affymetrix, developing array-based resequencing and genotyping technology. This effort was preceded by a postdoctoral research at Stanford University studying the electrophysiology of cystic fibrosis. Kevin holds a Ph.D. in biophysics and M.S. in physics from Stanford University. Kevin received his B.A. in math/physics from St. Olaf College.